How many drugs treat Bacterial pneumonia?

Drug Landscape tracks 10 marketed treatments for Bacterial pneumonia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bacterial-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bacterial pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacterial pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacterial pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xenleta	LEFAMULIN	Hong Kong	Pleuromutilin Antibacterial		2019-01-01
Nuzyra	OMADACYCLINE TOSYLATE	Paratek Pharms	Tetracycline-class Antibacterial [EPC]		2018-01-01
Nuzyra	OMADACYCLINE	Paratek Pharms	Tetracycline-class Antibacterial [EPC]		2018-01-01
Vibativ	TELAVANCIN	Cumberland	Lipoglycopeptide Antibacterial		2009-01-01
Vibativ	TELAVANCIN HYDROCHLORIDE	Cumberland	Lipoglycopeptide Antibacterial		2009-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 11 drugs in Bacterial pneumonia
Merck & Co. · 4 drugs in Bacterial pneumonia
GSK · 4 drugs in Bacterial pneumonia
Bristol-Myers Squibb · 3 drugs in Bacterial pneumonia
Bayer AG · 2 drugs in Bacterial pneumonia
Paratek Pharms · 2 drugs in Bacterial pneumonia
Merck Sharp & Dohme B.V. · 2 drugs in Bacterial pneumonia
Lg Chem Ltd · 2 drugs in Bacterial pneumonia
Cumberland · 2 drugs in Bacterial pneumonia
Baxter · 2 drugs in Bacterial pneumonia
Pai Holdings Pharm · 2 drugs in Bacterial pneumonia
Arbor Pharms Llc · 1 drug in Bacterial pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacterial pneumonia:

Cite this brief

Drug Landscape (2026). Bacterial pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacterial-pneumonia. Accessed 2026-06-10.

Bacterial pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing